CN101810629B - 一种甘油果糖组合物注射液及其制备方法 - Google Patents
一种甘油果糖组合物注射液及其制备方法 Download PDFInfo
- Publication number
- CN101810629B CN101810629B CN2009102239177A CN200910223917A CN101810629B CN 101810629 B CN101810629 B CN 101810629B CN 2009102239177 A CN2009102239177 A CN 2009102239177A CN 200910223917 A CN200910223917 A CN 200910223917A CN 101810629 B CN101810629 B CN 101810629B
- Authority
- CN
- China
- Prior art keywords
- fructose
- parts
- glycerol
- injection
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title claims abstract description 370
- 239000005715 Fructose Substances 0.000 title claims abstract description 136
- 229930091371 Fructose Natural products 0.000 title claims abstract description 134
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 title claims abstract description 134
- 238000002347 injection Methods 0.000 title claims abstract description 96
- 239000007924 injection Substances 0.000 title claims abstract description 96
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 88
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 67
- 239000008215 water for injection Substances 0.000 claims abstract description 66
- 239000000706 filtrate Substances 0.000 claims abstract description 62
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 60
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 54
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 54
- 238000003756 stirring Methods 0.000 claims abstract description 47
- 238000001914 filtration Methods 0.000 claims abstract description 43
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000243 solution Substances 0.000 claims abstract description 42
- 230000001954 sterilising effect Effects 0.000 claims abstract description 39
- 239000000463 material Substances 0.000 claims abstract description 22
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 47
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 47
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 35
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 35
- 239000000811 xylitol Substances 0.000 claims description 35
- 235000010447 xylitol Nutrition 0.000 claims description 35
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 35
- 229960002675 xylitol Drugs 0.000 claims description 35
- -1 maltose alcohols Chemical class 0.000 claims description 25
- 238000012856 packing Methods 0.000 claims description 24
- 239000012982 microporous membrane Substances 0.000 claims description 21
- 230000008901 benefit Effects 0.000 claims description 20
- 230000001105 regulatory effect Effects 0.000 claims description 20
- 239000003643 water by type Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000005855 radiation Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 238000004042 decolorization Methods 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 239000000845 maltitol Substances 0.000 abstract 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 abstract 1
- 229940035436 maltitol Drugs 0.000 abstract 1
- 235000010449 maltitol Nutrition 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 description 111
- 238000012360 testing method Methods 0.000 description 39
- 238000005352 clarification Methods 0.000 description 34
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 26
- 229930195725 Mannitol Natural products 0.000 description 26
- 239000000594 mannitol Substances 0.000 description 26
- 235000010355 mannitol Nutrition 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 14
- 235000001727 glucose Nutrition 0.000 description 14
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 206010018910 Haemolysis Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 150000002304 glucoses Chemical class 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000001177 diphosphate Substances 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 4
- 235000011180 diphosphates Nutrition 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005261 decarburization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011697 diabetes animal model Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
配方 | 1 | 2 | 3 | 4 |
吸收度 | 0.0138 | 0.0121 | 0.0142 | 0.2540 |
0.5h | 1h | 1.5h | 2h | 2.5h | 3h | 3.5h | 4h | |
1 | 0.009 | 0.009 | 0.010 | 0.011 | 0.013 | 0.014 | 0.016 | 0.020 |
2 | 0.009 | 0.010 | 0.011 | 0.013 | 0.014 | 0.016 | 0.019 | 0.024 |
3 | 0.010 | 0.011 | 0.014 | 0.017 | 0.021 | 0.025 | 0.031 | 0.045 |
4 | 0.009 | 0.012 | 0.016 | 0.021 | 0.028 | 0.037 | 0.051 | 0.069 |
4周 | 6周 | 8周 | 10周 | 12周 | 14周 | |
正常组 | 41.52 | 41.83 | 42.57 | 43.12 | 44.36 | 45.27 |
对照组 | 48.52 | 49.24 | 49.77 | 50.24 | 51.73 | 52.59 |
试验组1 | 48.23 | 49.17 | 50.14 | 50.38 | 51.69 | 52.71 |
试验组2 | 48.37 | 49.14 | 49.82 | 50.26 | 51.75 | 52.58 |
4周 | 6周 | 8周 | 10周 | 12周 | 14周 | |
正常组 | 7.58 | 7.92 | 8.12 | 7.95 | 8.04 | 7.69 |
对照组 | 16.15 | 16.97 | 18.51 | 18.98 | 19.57 | 21.15 |
试验组1 | 16.54 | 17.01 | 18.67 | 19.12 | 19.81 | 21.45 |
试验组2 | 16.37 | 16.85 | 19.11 | 20.84 | 21.24 | 22.51 |
碳(倍) | 5-HMF含量(吸光度) | 有关物质总含量(%) | 细菌内毒素 | |
1 | 0.1 | 0.0193 | 0.465 | 较差 |
2 | 0.2 | 0.0119 | 0.393 | 合格 |
3 | 0.7 | 0.0105 | 0.281 | 合格 |
4 | 1.0 | 0.0102 | 0.0217 | 合格 |
5 | 1.5 | 0.0101 | 0.0210 | 合格 |
6 | 2.0 | 0.0097 | 0.0204 | 合格 |
1个月 | 2个月 | 3个月 | 6个月 | 12个月 | |
1 | 0.281%澄清 | 0.282%澄清 | 0.287%澄清 | 0.372%澄清 | 0.654%澄清 |
2 | 0.294%澄清 | 0.294%澄清 | 0.298%澄清 | 0.379%澄清 | 0.798%澄清 |
3 | 0.289%澄清 | 0.292%澄清 | 0.395%澄清 | 0.627%析出固体 | 1.584%析出固体 |
4 | 0.286%澄清 | 0.297%澄清 | 0.352%澄清 | 0.579%析出固体 | 1.372%析出固体 |
3个月 | 6个月 | 9个月 | 12个月 | 18个月 | |
1 | 0.281%澄清 | 0.282%澄清 | 0.283%澄清 | 0.285%澄清 | 0.317%澄清 |
2 | 0.294%澄清 | 0.294%澄清 | 0.295%澄清 | 0.298%澄清 | 0.358%澄清 |
3 | 0.289%澄清 | 0.289%澄清 | 0.298%澄清 | 0.324%澄清 | 0.827%析出固体 |
4 | 0.286%澄清 | 0.286%澄清 | 0.295%澄清 | 0.330%澄清 | 0.851%析出固体 |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102239177A CN101810629B (zh) | 2009-11-19 | 2009-11-19 | 一种甘油果糖组合物注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102239177A CN101810629B (zh) | 2009-11-19 | 2009-11-19 | 一种甘油果糖组合物注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101810629A CN101810629A (zh) | 2010-08-25 |
CN101810629B true CN101810629B (zh) | 2011-11-09 |
Family
ID=42618090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102239177A Active CN101810629B (zh) | 2009-11-19 | 2009-11-19 | 一种甘油果糖组合物注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101810629B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102526099A (zh) * | 2011-12-23 | 2012-07-04 | 蚌埠丰原涂山制药有限公司 | 一种甘油果糖氯化钠注射液及其制备方法 |
CN102488696A (zh) * | 2011-12-30 | 2012-06-13 | 南京正大天晴制药有限公司 | 一种甘油果糖组合物注射液及其制备方法 |
CN102631842B (zh) * | 2012-04-12 | 2014-09-10 | 江苏久吾高科技股份有限公司 | 去除生物医药制剂中内毒素的方法 |
CN102657677B (zh) * | 2012-04-28 | 2013-03-06 | 天津金耀集团有限公司 | 一种甘油果糖氯化钠注射液 |
-
2009
- 2009-11-19 CN CN2009102239177A patent/CN101810629B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN101810629A (zh) | 2010-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101810629B (zh) | 一种甘油果糖组合物注射液及其制备方法 | |
CN101190214B (zh) | 紫杉醇注射液及其制备方法 | |
CN104856946B (zh) | 一种地塞米松磷酸钠注射液及其制备工艺 | |
CN110538144A (zh) | 一种奥硝唑注射液和s-奥硝唑注射液 | |
CN101417105B (zh) | 一种莪术油葡萄糖注射液及其制备方法 | |
CN101167717B (zh) | 一种新型单硝酸异山梨酯注射液 | |
CN1830428A (zh) | 一种阿魏酸钠注射液及其制备方法和用途 | |
CN110251461B (zh) | 复合维生素b注射液及其制备方法 | |
CN106361969A (zh) | 一种提高参麦药物注射制剂稳定性药物组合物的制备方法 | |
CN102335129B (zh) | 一种供注射用依达拉奉药物组合物及其制备方法 | |
CN101890061B (zh) | 银杏叶提取物注射液的制备方法及其银杏叶提取物注射液 | |
CN1049132C (zh) | 丹参注射液 | |
RU2524651C1 (ru) | Фармацевтическая композиция в форме раствора для инъекций и способ ее получения | |
CN101569612A (zh) | 一种克林霉素磷酸酯冻干粉针试剂 | |
CN106389315A (zh) | 一种提高益智仁药物注射制剂稳定性的注射用药物组合物 | |
CN108721625A (zh) | 抗生素药物的果糖注射液 | |
CN106344502A (zh) | 一种提高水蛭药物注射制剂稳定性的注射用药物组合物 | |
CN106361693A (zh) | 一种水蛭注射制剂药物组合物的制备方法 | |
CN1919219A (zh) | 银杏总黄酮的精制方法及制备银杏达莫注射液的方法 | |
CN109125256A (zh) | 一种氢化泼尼松注射液及其制备方法 | |
CN103877015B (zh) | 一种盐酸溴己新葡萄糖注射液的制备方法 | |
CN105878180A (zh) | 一种提高栀子苷药物注射制剂稳定性的注射用药物组合物 | |
CN106389316A (zh) | 一种提高青蒿药物注射制剂稳定性的注射用药物组合物 | |
CN105935351A (zh) | 一种提高水飞蓟素药物注射制剂稳定性的注射用药物组合物 | |
CN112426359A (zh) | 双室袋含糖林格液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shanxi Nuocheng Pharmaceutical Co., Ltd. Assignor: Luo Cheng Contract record no.: 2011990000815 Denomination of invention: Composition injection of glycerol and fructose and preparation method thereof License type: Common License Open date: 20100825 Record date: 20110824 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100825 Assignee: Fujian Tianquan Pharmaceutical Company Limited Assignor: Luo Cheng Contract record no.: 2012990000816 Denomination of invention: Composition injection of glycerol and fructose and preparation method thereof Granted publication date: 20111109 License type: Common License Record date: 20121102 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100825 Assignee: Shijiazhuang No.4 Pharmaceutical Co., Ltd. Assignor: Luo Cheng Contract record no.: 2013990000408 Denomination of invention: Composition injection of glycerol and fructose and preparation method thereof Granted publication date: 20111109 License type: Common License Record date: 20130719 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Fujian Tianquan Pharmaceutical Company Limited Assignor: Luo Cheng Contract record no.: 2012990000816 Date of cancellation: 20140402 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100825 Assignee: Fujian Tianquan Pharmaceutical Company Limited Assignor: Luo Cheng Contract record no.: 2014990000168 Denomination of invention: Composition injection of glycerol and fructose and preparation method thereof Granted publication date: 20111109 License type: Common License Record date: 20140402 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100825 Assignee: SICHUAN TAIPINGYANG PHARMACEUTICAL CO., LTD. Assignor: Luo Cheng Contract record no.: 2016990000003 Denomination of invention: Composition injection of glycerol and fructose and preparation method thereof Granted publication date: 20111109 License type: Common License Record date: 20160111 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: SICHUAN TAIPINGYANG PHARMACEUTICAL CO., LTD. Assignor: Luo Cheng Contract record no.: 2016990000003 Date of cancellation: 20180606 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20100825 Assignee: SICHUAN TAIPINGYANG PHARMACEUTICAL CO., LTD. Assignor: Luo Cheng Contract record no.: 2018990000152 Denomination of invention: Composition injection of glycerol and fructose and preparation method thereof Granted publication date: 20111109 License type: Common License Record date: 20180608 |
|
EE01 | Entry into force of recordation of patent licensing contract |